Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | AVPR1A | P37288 | 10/20 | 0.52 |
| ▸ | AVPR2 | P30518 | 7/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14534438 | 1.00 | ALDH1A1 (0.56) | ALDH1A1MEN1HTTKMT2ATDP1 | |
| SCHEMBL2895065 | 0.86 | ALDH1A1 (0.54) | ALDH1A1MEN1HTTKMT2ATDP1 | |
| SCHEMBL2895118 | 0.84 | ALDH1A1 (0.56) | ALDH1A1MEN1HTTKMT2ATDP1 | |
| SCHEMBL2895595 | 0.84 | ALDH1A1 (0.56) | ALDH1A1MEN1HTTKMT2ATDP1 | |
| SCHEMBL2895729 | 0.82 | ALDH1A1 (0.65) | ALDH1A1MEN1HTTKMT2ATDP1 | |
| SCHEMBL1393533 | 0.81 | ALDH1A1 (0.63) | ALDH1A1MEN1HTTKMT2ATDP1 | |
| SCHEMBL2895086 | 0.79 | ALDH1A1 (0.70) | ALDH1A1MEN1HTTKMT2ATDP1 | |
| SCHEMBL2889424 | 0.78 | ALDH1A1 (0.61) | ALDH1A1MEN1HTTKMT2ATDP1 | |
| SCHEMBL2895108 | 0.78 | ALDH1A1 (0.51) | ALDH1A1MEN1HTTKMT2ATDP1 | |
| SCHEMBL3455905 | 0.77 | ALDH1A1 (0.67) | ALDH1A1MEN1HTTKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120743-A1 | 11Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-05-13 | — | — | US | claimed |
| EP-1787982-B1 | 11Beta-Hydroxysteroid dehydrogenase type 1 active compounds | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-05-12 | — | — | EP | claimed |
| US-7700583-B2 | Such as [4-(1,3,3-Trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-phenyl]carbamic acid tert-butyl ester; for treatment of metabolic syndrome | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-04-20 | — | — | US | claimed |
| EP-1787982-A2 | 11Beta-Hydroxysteroid dehydrogenase type 1 active compounds | Novo Nordisk A/S (DK) | 2007-05-23 | — | — | EP | claimed |
| US-20060089349-A1 | 11beta-hydroxysteroid dehydrogenase type 1 active compounds | NOVO NORDISK A/S (DK) | 2006-04-27 | — | — | US | claimed |
| US-20100120743-A1 | 11Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120743-A1 | 11Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120743-A1 | 11Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-05-13 | — | — | US | disclosed |
| EP-1787982-B1 | 11Beta-Hydroxysteroid dehydrogenase type 1 active compounds | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-05-12 | — | — | EP | disclosed |
| EP-1787982-B1 | 11Beta-Hydroxysteroid dehydrogenase type 1 active compounds | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-05-12 | — | — | EP | disclosed |
| US-7700583-B2 | Such as [4-(1,3,3-Trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-phenyl]carbamic acid tert-butyl ester; for treatment of metabolic syndrome | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700583-B2 | Such as [4-(1,3,3-Trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-phenyl]carbamic acid tert-butyl ester; for treatment of metabolic syndrome | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700583-B2 | Such as [4-(1,3,3-Trimethyl-6-aza-bicyclo[3.2.1]octane-6-carbonyl)-phenyl]carbamic acid tert-butyl ester; for treatment of metabolic syndrome | HIGH POINT PHARMACEUTICALS, LLC (US) | 2010-04-20 | — | — | US | disclosed |
| EP-1787982-A2 | 11Beta-Hydroxysteroid dehydrogenase type 1 active compounds | Novo Nordisk A/S (DK) | 2007-05-23 | — | — | EP | disclosed |
| US-20060089349-A1 | 11beta-hydroxysteroid dehydrogenase type 1 active compounds | NOVO NORDISK A/S (DK) | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120743-A1 | 11Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HSD11B1, HSD3B1, HSD17B1 | ALDH1A1 59/4885MEN1 1304/4885HTT 3150/4885 |
| US-20060089349-A1 | 11beta-hydroxysteroid dehydrogenase type 1 active compounds | HSD11B1, HSD3B1, HSD17B1 | ALDH1A1 59/4885MEN1 1304/4885HTT 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.